142 related articles for article (PubMed ID: 17471166)
1. In vitro antitumoral activity of baculovirus-expressed chimeric recombinant anti-CD4 antibody 13B8.2 on T-cell lymphomas.
Troadec S; Chentouf M; Cérutti M; Nguyen B; Olive D; Bès C; Chardès T
J Immunother; 2007; 30(2):190-202. PubMed ID: 17471166
[TBL] [Abstract][Full Text] [Related]
2. Biological activities on T lymphocytes of a baculovirus-expressed chimeric recombinant IgG1 antibody with specificity for the CDR3-like loop on the D1 domain of the CD4 molecule.
Troadec S; Bès C; Chentouf M; Nguyen B; Briant L; Jacquet C; Chebli K; Pugnière M; Roquet F; Cerutti M; Chardès T
Clin Immunol; 2006 Apr; 119(1):38-50. PubMed ID: 16426893
[TBL] [Abstract][Full Text] [Related]
3. The chimeric mouse-human anti-CD4 Fab 13B8.2 expressed in baculovirus inhibits both antigen presentation and HIV-1 promoter activation.
Bès C; Cerutti M; Briant-Longuet L; Bresson D; Peraldi-Roux S; Pugnière M; Mani JC; Pau B; Devaux C; Granier C; Devauchelle G; Chardès T
Hum Antibodies; 2001; 10(2):67-76. PubMed ID: 11673661
[TBL] [Abstract][Full Text] [Related]
4. An anti-CD4 (CDR3-loop) monoclonal antibody inhibits human immunodeficiency virus type 1 envelope glycoprotein-induced apoptosis.
Guillerm C; Robert-Hebmann V; Hibner U; Hirn M; Devaux C
Virology; 1998 Sep; 248(2):254-63. PubMed ID: 9721234
[TBL] [Abstract][Full Text] [Related]
5. The lipid-modulating effects of a CD4-specific recombinant antibody correlate with ZAP-70 segregation outside membrane rafts.
Chentouf M; Rigo M; Ghannam S; Navarro-Teulon I; Mongrand S; Pèlegrin A; Chardès T
Immunol Lett; 2010 Oct; 133(2):62-9. PubMed ID: 20659502
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV-1 replication by a monoclonal antibody directed toward the complementarity determining region 3-like domain of CD4 in CD45 expressing and CD45-deficient cells.
Péléraux A; Peyron JF; Devaux C
Virology; 1998 Mar; 242(1):233-7. PubMed ID: 9501032
[TBL] [Abstract][Full Text] [Related]
7. Chimaeric anti-CD4 monoclonal antibody cross-linked by monocyte Fc gamma receptor mediates apoptosis of human CD4 lymphocytes.
Choy EH; Adjaye J; Forrest L; Kingsley GH; Panayi GS
Eur J Immunol; 1993 Oct; 23(10):2676-81. PubMed ID: 8104799
[TBL] [Abstract][Full Text] [Related]
8. Expression of the CR1 receptor on human leukemia-derived CD4+ T cell lines.
Yaskanin DD; Waxman FJ
Cell Immunol; 1995 Jun; 163(1):139-47. PubMed ID: 7758124
[TBL] [Abstract][Full Text] [Related]
9. Recombinant anti-CD4 antibody 13B8.2 blocks membrane-proximal events by excluding the Zap70 molecule and downstream targets SLP-76, PLC gamma 1, and Vav-1 from the CD4-segregated Brij 98 detergent-resistant raft domains.
Chentouf M; Ghannam S; Bès C; Troadec S; Cérutti M; Chardès T
J Immunol; 2007 Jul; 179(1):409-20. PubMed ID: 17579062
[TBL] [Abstract][Full Text] [Related]
10. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system.
Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL
Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752
[TBL] [Abstract][Full Text] [Related]
11. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
Law CL; Gordon KA; Collier J; Klussman K; McEarchern JA; Cerveny CG; Mixan BJ; Lee WP; Lin Z; Valdez P; Wahl AF; Grewal IS
Cancer Res; 2005 Sep; 65(18):8331-8. PubMed ID: 16166310
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of anti-CD4-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies.
Alters SE; Sakai K; Steinman L; Oi VT
J Immunol; 1990 Jun; 144(12):4587-92. PubMed ID: 1972161
[TBL] [Abstract][Full Text] [Related]
13. An antibody that binds domain 1 of CD4 inhibits replication of HIV-1, but not HTLV-I, in a CD4-positive/p56lck-negative HTLV-I-transformed cell line.
Lemasson I; Briant L; Hague B; Coudronnière N; Heron L; David C; Rebouissou C; Kindt T; Devaux C
J Immunol; 1996 Jan; 156(2):859-65. PubMed ID: 8543843
[TBL] [Abstract][Full Text] [Related]
14. CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells.
Wulf GG; Boehnke A; Chapuy B; Glass B; Hemmerlein B; Schroers R; Brenner MK; Truemper L
Haematologica; 2006 Jul; 91(7):886-94. PubMed ID: 16818275
[TBL] [Abstract][Full Text] [Related]
15. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
[TBL] [Abstract][Full Text] [Related]
16. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
17. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
18. High-level expression and characterization of a mouse-human chimeric CD4 antibody with therapeutic potential.
Looney JE; Knight DM; Arevalo-Moore M; Trinh H; Pak KY; Dalesandro MR; Rieber EP; Riethmuller G; Daddona PE; Ghrayeb J
Hum Antibodies Hybridomas; 1992 Oct; 3(4):191-200. PubMed ID: 1477300
[TBL] [Abstract][Full Text] [Related]
19. The novel chimeric anti-NCAM (neural cell adhesion molecule) antibody ch.MK1 displays antitumor activity in SCID mice but does not activate complement-dependent cytolysis (CDC).
Klehr M; Koehl U; Mühlenhoff M; Tawadros S; Fischer T; Schomäcker K; Heuckmann JM; Bochennek K; Jensen M
J Immunother; 2009 Jun; 32(5):442-51. PubMed ID: 19609236
[TBL] [Abstract][Full Text] [Related]
20. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
Newman R; Hariharan K; Reff M; Anderson DR; Braslawsky G; Santoro D; Hanna N; Bugelski PJ; Brigham-Burke M; Crysler C; Gagnon RC; Dal Monte P; Doyle ML; Hensley PC; Reddy MP; Sweet RW; Truneh A
Clin Immunol; 2001 Feb; 98(2):164-74. PubMed ID: 11161972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
